Organization
European Organisation for Research and Treatment of Cancer
47 clinical trials
3 abstracts
Abstract
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.Org: University Hospital Zurich, Brain Tumor Centre, University of Zurich, EORTC Headquarters, Institute of Neuropathology,
Clinical trial
Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)Status: Terminated, Estimated PCD: 2023-04-04
Clinical trial
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIALStatus: Active (not recruiting), Estimated PCD: 2022-12-22
Clinical trial
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA RelapseStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]Status: , Estimated PCD: 1998-10-01
Clinical trial
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors; a Phase 3 Pragmatic Randomized Trial.Status: Not yet recruiting, Estimated PCD: 2029-09-15
Clinical trial
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")Status: Completed, Estimated PCD: 2017-12-06
Clinical trial
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung CancerStatus: Completed, Estimated PCD: 2020-09-22
Clinical trial
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCGStatus: Active (not recruiting), Estimated PCD: 2023-11-06
Clinical trial
Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic TreatmentStatus: Terminated, Estimated PCD: 2021-03-11
Clinical trial
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Completed, Estimated PCD: 2019-05-15
Clinical trial
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed GlioblastomaStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer GroupStatus: Active (not recruiting), Estimated PCD: 2024-03-26
Clinical trial
MOGAT: Open-Label, Phase II, Multi-Centre, Study of Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK InhibitorStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract CancerStatus: Completed, Estimated PCD: 2023-04-27
Clinical trial
Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.Status: Active (not recruiting), Estimated PCD: 2018-09-05
Clinical trial
a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Every Three Weeks or Doxorubicin Weekly or Cyclophosphamide Plus Predniso(lo)ne TreatmentStatus: Terminated, Estimated PCD: 2023-09-22
Clinical trial
A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
SPECTA: Screening Cancer Patients for Efficient Clinical Trial AccessStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2027-04-14
Clinical trial
Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic SubgroupsStatus: , Estimated PCD: 2004-05-01
Clinical trial
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's LymphomaStatus: , Estimated PCD: 2010-01-01
Clinical trial
Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast CancerStatus: Withdrawn, Estimated PCD: 2028-09-06
Clinical trial
Pharmacokinetics Study of Combined Treatment Lapatinib and Tamoxifen in Advanced/Metastatic Breast CancerStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Radiotherapy Plus Xevinapant or Placebo in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: a Randomized Phase II Study RAVINAStatus: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-01-13
Clinical trial
Pembrolizumab and Radiotherapy for OLigometastatic Squamous Cell Carcinoma of the Head and Neck: a Randomized Phase III StudyStatus: Not yet recruiting, Estimated PCD: 2027-07-15
Clinical trial
Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's DiseaseStatus: , Estimated PCD: 2000-05-01
Clinical trial
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer; A Pragmatic Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2028-04-18
Clinical trial
Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia GroupsStatus: Completed, Estimated PCD: 2019-04-04
Clinical trial
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III StudyStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.Status: Active (not recruiting), Estimated PCD: 2024-02-19
Clinical trial
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)Status: Recruiting, Estimated PCD: 2027-04-21
Clinical trial
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line TreatmentStatus: Active (not recruiting), Estimated PCD: 2022-03-01
Clinical trial
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)Status: Active (not recruiting), Estimated PCD: 2023-08-23
Clinical trial
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)Status: Active (not recruiting), Estimated PCD: 2023-10-24
Clinical trial
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCStatus: Not yet recruiting, Estimated PCD: 2030-01-01
Clinical trial
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*0201 Positive Patients With High-risk Non-metastatic Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Status: Not yet recruiting, Estimated PCD: 2032-11-01
Clinical trial
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-studyStatus: Active (not recruiting), Estimated PCD: 2023-12-12
Clinical trial
Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-methylated Glioblastoma: a Randomized Phase II Open Label Multicenter StudyStatus: Withdrawn, Estimated PCD: 2022-12-19
Clinical trial
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal AdenocarcinomaStatus: Completed, Estimated PCD: 2021-06-01
Clinical trial
10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study GroupStatus: Active (not recruiting), Estimated PCD: 2022-03-07
Clinical trial
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- IpilimumabStatus: Terminated, Estimated PCD: 2022-10-07
Clinical trial
A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Abstract
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.Org: North Estonia Medical Centre Foundation, The Catholic University of Korea, Hiroshima University Hospital, Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,